Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

EDIT vs PACB: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

EDIT Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 5–3 Matrix Metrics)

EDIT Overall Winner 6-Pillar Tally: EDIT 5 – 1 PACB Matrix Metrics: EDIT 5 – 3 PACB

As of Nov 16, 2026, Editas Medicine, Inc. (EDIT) is the stronger overall head-to-head candidate over Pacific Biosciences of California, Inc. (PACB) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). EDIT carries a Unified Composite Score of 51.6/100 (HOLD) at $1.91 (N/M Forward P/E, -167.0% operating margin), whereas PACB carries 38.0/100 (SELL) at $1.89 (N/M Forward P/E, -333.0% operating margin).

  • Technical & Structure Timing Caution: EDIT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 35.1); meanwhile PACB is in a Breakdown options structure phase (RSI 40.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About EDIT vs PACB
EDIT NASDAQ Head-to-Head Winner
Editas Medicine, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$1.91
-12.21% 1D
Market Cap $336.5M
TTM Revenue $50M
Forward P/E N/M
Beta / 30D Vol 2.32β · 102% Vol
Unified Composite Score
51.6 / 100 HOLD
Tech 40.0 Fund 54.0 Flow 69.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.3%), weak momentum, RSI 35
RSI-14: 35.1 · SMA20: $2.52 · SMA50: $2.61
PACB NASDAQ
Pacific Biosciences of California, Inc.
Laboratory Analytical Instruments
$1.89
-3.83% 1D
Market Cap $615.1M
TTM Revenue $161M
Forward P/E N/M
Beta / 30D Vol 2.27β · 112% Vol
Unified Composite Score
38.0 / 100 SELL
Tech 15.0 Fund 35.0 Flow 57.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 41
RSI-14: 40.8 · SMA20: $2.29 · SMA50: $2.02

6-Pillar Scorecard Institutional Category Breakdown (EDIT 5 – 1 PACB)

Columns: Metric · EDIT · PACB
1. Valuation Multiples EDIT
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 5.2x 7.8x
2. Growth & Scale PACB
Revenue Growth (YoY) +37.4% +5.5%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $50M $161M
Market Cap $336.5M $615.1M
3. Profitability & Quality EDIT
Gross Margin -73.3% 27.7%
Operating Margin -167.0% -333.0%
Net Profit Margin -144.9% -81.3%
Return on Equity (ROE) -147.4% -929.3%
4. Balance Sheet & Cash Flow EDIT
Cash Generation (TTM) -$110M -$150M
Cash Flow Margin N/A -93.2%
Net Cash / Leverage $79M Net Cash $649M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning EDIT
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 95.8% (38th %ile) 92.6% (47th %ile)
Put/Call OI Skew 0.29x (Call-Skewed) 0.19x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat EDIT
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Concentrated Oligopoly Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: EDIT (5) vs PACB (3)
Institutional Metric EDIT PACB Criterion Row Edge
Market Capitalization
Scale
$336.5M $615.1M Larger Scale PACB
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+37.4% +5.5% Higher Growth EDIT
Operating Margin (TTM)
Profitability
-167.0% -333.0% Higher Margin EDIT
Net Profit Margin
Profitability
-144.9% -81.3% Higher Margin PACB
Return on Equity (ROE)
Capital Efficiency
-147.4% -929.3% Higher ROE EDIT
52-Week Range Position
Momentum
11% ($2–$4) 34% ($1–$3) Stronger Trend PACB
Beta / 30D Volatility
Risk Regime
2.32β · 102% Vol 2.27β · 112% Vol Lower Realized Risk EDIT
Unified Institutional Score
Composite Signal
51.6 / 100 (HOLD) 38.0 / 100 (SELL) Higher Composite EDIT
Trailing 12M Revenue (USD)
Operating Scale
$50M $161M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-73.3% 27.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 5.2x EV/Rev N/M PEG · 7.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$110M ($79M Net Cash) -$150M ($649M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PACB +27.9 pp
EDIT: -18.94% · PACB: +8.96%
3M Horizon PACB +99.2 pp
EDIT: -33.85% · PACB: +65.35%
6M Horizon PACB +88.61 pp
EDIT: -24.7% · PACB: +63.91%
1Y Horizon PACB +40.64 pp
EDIT: -25.0% · PACB: +15.64%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period EDIT Revenue PACB Revenue EDIT Op. Margin PACB Op. Margin Margin Leader
FY2018 $30M $80M -356.1% -128.4% PACB
FY2019 $20M $90M -686.4% -110.6% PACB
FY2020 $90M $80M -148.6% -132.3% PACB
FY2021 $30M $130M -756.1% -161.2% PACB
FY2022 $20M $130M -1146.3% -239.4% PACB
FY2023 $80M $200M -216.6% -166.8% PACB
FY2024 $30M $150M -777.2% -308.0% PACB
FY2025 $40M $160M -394.9% -346.2% PACB

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
EDIT BREAKDOWN
146d in phase · OBV NEUTRAL
Current IV 95.8%
IV Percentile 38th %ile
Put/Call OI Skew 0.29x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact EDIT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PACB BREAKDOWN
12d in phase · OBV DISTRIBUTION
Current IV 92.6%
IV Percentile 47th %ile
Put/Call OI Skew 0.19x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact PACB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
EDIT Moat Profile Concentrated Oligopoly Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $336.5M market capitalization and -167.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published · CRISPR / Gene Editing
PACB Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $615.1M market capitalization and -333.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ EDIT vs PACB Key Questions & Quantitative Answers

As of Nov 16, 2026, Editas Medicine, Inc. (EDIT) is the stronger overall head-to-head candidate over Pacific Biosciences of California, Inc. (PACB) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). EDIT carries a Unified Composite Score of 51.6/100 (HOLD) at $1.91 (N/M Forward P/E, -167.0% operating margin), whereas PACB carries 38.0/100 (SELL) at $1.89 (N/M Forward P/E, -333.0% operating margin). Technical & Structure Timing Caution: EDIT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 35.1); meanwhile PACB is in a Breakdown options structure phase (RSI 40.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

PACB leads the Growth & Scale pillar: EDIT posts +37.4% YoY revenue growth and +0.0% YoY earnings growth on $50M TTM revenue (-73.3% gross margin, -167.0% operating margin), compared with PACB at +5.5% YoY revenue growth and +0.0% YoY earnings growth on $161M TTM revenue (27.7% gross margin, -333.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), EDIT cumulative revenue shifted +33.3% while PACB shifted +100.0%. In operating R&D and SG&A reinvestment, EDIT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PACB.

EDIT screens cheaper on headline valuation multiples. EDIT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 5.2x EV/Revenue (unreported FCF margin), whereas PACB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 7.8x EV/Revenue (-93.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EDIT (-147.4% ROE) versus PACB (-929.3% ROE) capital efficiency.

In options market volatility and institutional positioning, EDIT carries 95.8% implied volatility (38th %ile, Balanced (25th–60th %ile)), a 0.29x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (2.32β · 102% Vol realized risk). By comparison, PACB carries 92.6% implied volatility (47th %ile, Balanced (25th–60th %ile)), a 0.19x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.27β · 112% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.